{"id":47424,"date":"2022-08-18T12:02:07","date_gmt":"2022-08-18T10:02:07","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/continuous-renal-replacement-therapy-crrt-global-market-trajectory-analytics-to-2026-researchandmarkets-com\/"},"modified":"2022-08-18T12:02:07","modified_gmt":"2022-08-18T10:02:07","slug":"continuous-renal-replacement-therapy-crrt-global-market-trajectory-analytics-to-2026-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/continuous-renal-replacement-therapy-crrt-global-market-trajectory-analytics-to-2026-researchandmarkets-com\/","title":{"rendered":"Continuous Renal Replacement Therapy (CRRT) – Global Market Trajectory & Analytics to 2026 – ResearchAndMarkets.com"},"content":{"rendered":"
\n

DUBLIN–(BUSINESS WIRE)–The “Continuous Renal Replacement Therapy (CRRT) – Global Market Trajectory & Analytics”<\/a> report has been added to ResearchAndMarkets.com’s<\/strong> offering.\n<\/p>\n

<\/a><\/p>\n

\nGlobal Continuous Renal Replacement Therapy (CRRT) Market to Reach $1.7 Billion by 2026<\/strong>\n<\/p>\n

\nAmid the COVID-19 crisis, the global market for Continuous Renal Replacement Therapy (CRRT) estimated at US$1.4 Billion in the year 2022, is projected to reach a revised size of US$1.7 Billion by 2026, registering a compounded annual growth rate (CAGR) of 5.8% over the analysis period.\n<\/p>\n

\nContinuous renal replacement therapy (CRRT) is the most widely used therapy in critically ill patients as these hypotensive patients require slow removal of waste and water without causing hypotension. As renal replacement therapy for pediatric patients with Acute Kidney Injury (AKI) becomes more commonplace, CRRT gains traction as a suitable treatment modality for patients of any size and who are hemodynamically unstable. The growing prevalence of cardiovascular diseases is the underlying factor for acute kidney injury cases, which is expected to drive the demand for CRRT.\n<\/p>\n

\nThe United States represents the largest regional market for Continuous Renal Replacement Therapy (CRRT), and is projected to reach US$422.4 Million by 2026. China is expected to spearhead growth and emerge as the fastest growing regional market with a CAGR of 8.3% over the analysis period.\n<\/p>\n

\nThe global Continuous Renal Replacement Therapy (CRRT) market is expected to increase rapidly in future, driven by rising incidence of acute kidney injury (AKI). AKI constitutes for about 60% mortality rate. CRRT is the most widely used treatment for AKI. The technique is the most preferred modality for treating and managing hemodynamically unstable patients with AKI.\n<\/p>\n

\nBenefits of CRRT include hemodynamic tolerance due to solute removal and slower ultrafiltration. Rise in ageing population, increase in ICU-related admissions, and higher acceptance of CRRT procedures due to clinical advantages over the intermittent blood purification methods are the other key factors driving market growth.\n<\/p>\n

\nAs Renal replacement therapy (RRT) is required in patients with severe acute kidney injury (AKI), the rise in incidence of Acute Kidney Injury remains a major factor driving growth in the CRRT market. Renal disorders and kidney related ailments are also common among aged people, and spike in population of aged people inflates the potential patient population for CRRT treatments.\n<\/p>\n

\nEurope and the United States dominate the Continuous Renal Replacement Therapy market, driven by the fast growing aging population and increasing acute kidney injury cases. Growth in Asia-Pacific region is attributable to increasing aging population, rising cases of acute kidney injury\/diseases, increasing healthcare expenditure, technological advancements, and governments’ push for investments in the healthcare sector.\n<\/p>\n

\nThe market for Continuous Venovenous Hemodiafiltration (CVVHDF) is forecast to grow at the fastest rate among all modalities over the analysis period. CVVHDF treatment modality leads to comprehensive removal and replacement of fluids and blood in the blood.\n<\/p>\n

\nThe modality combines the principles of convection and diffusion, hemodialysis and hemofiltration, by using an efficient hemodiafilter. Given the modality’s ability to eliminate solute as well as fluid, the CVVHDF segment is poised to grow at a strong pace in the coming years. CVVHDF is a modality that is generally preferred among hospitals equipped with well-established intensive care units.\n<\/p>\n

\nWhat’s New for 2022?<\/strong>\n<\/p>\n